Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 13 |
| List of Tables | 13 | 1 |
| List of Figures | 14 | 1 |
| Introduction | 15 | 1 |
| Global Markets Direct Report Coverage | 15 | 1 |
| Dengue Fever Overview | 16 | 1 |
| Therapeutics Development | 17 | 2 |
| Pipeline Products for Dengue Fever Overview | 17 | 1 |
| Pipeline Products for Dengue Fever Comparative Analysis | 18 | 1 |
| Dengue Fever Therapeutics under Development by Companies | 19 | 3 |
| Dengue Fever Therapeutics under Investigation by Universities/Institutes | 22 | 2 |
| Dengue Fever Pipeline Products Glance | 24 | 3 |
| Late Stage Products | 24 | 1 |
| Clinical Stage Products | 25 | 1 |
| Early Stage Products | 26 | 1 |
| Dengue Fever Products under Development by Companies | 27 | 4 |
| Dengue Fever Products under Investigation by Universities/Institutes | 31 | 2 |
| Dengue Fever Companies Involved in Therapeutics Development | 33 | 36 |
| Abivax S.A. | 33 | 1 |
| Agilvax, Inc. | 34 | 1 |
| Altravax, Inc. | 35 | 1 |
| Arbovax, Inc. | 36 | 1 |
| BCI Pharma | 37 | 1 |
| Bioneer Corporation | 38 | 1 |
| Biotron Limited | 39 | 1 |
| CalAsia Pharmaceuticals, Inc. | 40 | 1 |
| Cocrystal Pharma, Inc. | 41 | 1 |
| Codagenix, Inc. | 42 | 1 |
| Emergent BioSolutions Inc. | 43 | 1 |
| Ennaid Therapeutics, LLC | 44 | 1 |
| GlaxoSmithKline Plc | 45 | 1 |
| Globavir Biosciences, Inc. | 46 | 1 |
| Hawaii Biotech, Inc. | 47 | 1 |
| Humabs BioMed SA | 48 | 1 |
| Immunotope, Inc. | 49 | 1 |
| Immunovaccine, Inc. | 50 | 1 |
| Inovio Pharmaceuticals, Inc. | 51 | 1 |
| Johnson &Johnson | 52 | 1 |
| Kineta, Inc. | 53 | 1 |
| Merck &Co., Inc. | 54 | 1 |
| Molplex Ltd. | 55 | 1 |
| NanoViricides, Inc. | 56 | 1 |
| Novartis AG | 57 | 1 |
| NovaTarg Therapeutics, Inc | 58 | 1 |
| Panacea Biotec Limited | 59 | 1 |
| ProtInhi B.V. | 60 | 1 |
| Sanofi Pasteur SA | 61 | 1 |
| Sarepta Therapeutics, Inc. | 62 | 1 |
| SIGA Technologies, Inc. | 63 | 1 |
| Takeda Pharmaceutical Company Limited | 64 | 1 |
| TechnoVax, Inc. | 65 | 1 |
| Themis Bioscience GmbH | 66 | 1 |
| VaxInnate Corporation | 67 | 1 |
| Visterra, Inc. | 68 | 1 |
| Dengue Fever Therapeutics Assessment | 69 | 9 |
| Assessment by Monotherapy Products | 69 | 1 |
| Assessment by Target | 70 | 2 |
| Assessment by Mechanism of Action | 72 | 2 |
| Assessment by Route of Administration | 74 | 2 |
| Assessment by Molecule Type | 76 | 2 |
| Drug Profiles | 78 | 109 |
| ABX-220 Drug Profile | 78 | 1 |
| ABX-221 Drug Profile | 79 | 1 |
| Antisense RNAi Oligonucleotide for Dengue Drug Profile | 80 | 1 |
| Antisense RNAi Oligonucleotide for Dengue Drug Profile | 81 | 1 |
| BRM-211 Drug Profile | 82 | 1 |
| CDX-DENV-14 Drug Profile | 83 | 1 |
| celgosivir hydrochloride Drug Profile | 84 | 1 |
| dengue (tetravalent) vaccine Drug Profile | 85 | 1 |
| dengue (tetravalent) vaccine Drug Profile | 86 | 1 |
| dengue (tetravalent) vaccine Drug Profile | 87 | 1 |
| dengue (tetravalent) vaccine Drug Profile | 88 | 1 |
| dengue (tetravalent) vaccine Drug Profile | 89 | 1 |
| dengue (tetravalent) vaccine Drug Profile | 90 | 1 |
| dengue (tetravalent) vaccine Drug Profile | 91 | 1 |
| dengue (tetravalent) vaccine 4 Drug Profile | 92 | 1 |
| dengue (tetravalent) vaccines Drug Profile | 93 | 1 |
| dengue (virus like particle) vaccine Drug Profile | 94 | 1 |
| dengue (virus like particle) vaccine Drug Profile | 95 | 1 |
| dengue [serotype 1] vaccine Drug Profile | 96 | 1 |
| dengue [serotype 2] (monovalent) vaccine Drug Profile | 97 | 1 |
| dengue [serotype 2] vaccine Drug Profile | 98 | 1 |
| dengue [serotype 3] (monovalent) vaccine Drug Profile | 99 | 1 |
| dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine Drug Profile | 100 | 4 |
| dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine Drug Profile | 104 | 1 |
| dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine Drug Profile | 105 | 1 |
| dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine Drug Profile | 106 | 1 |
| dengue [serotypes 1, 2, 3, 4] (tetravalent) virus like particle vaccine Drug Profile | 107 | 1 |
| dengue [serotypes 1, 2] vaccine Drug Profile | 108 | 1 |
| dengue [serotypes 1, 3, 4] (trivalent) vaccine Drug Profile | 109 | 1 |
| dengue vaccine Drug Profile | 110 | 2 |
| dengue vaccine Drug Profile | 112 | 1 |
| dengue vaccine Drug Profile | 113 | 1 |
| dengue vaccine Drug Profile | 114 | 1 |
| dengue vaccine Drug Profile | 115 | 1 |
| dengue vaccine Drug Profile | 116 | 1 |
| DengueCide Drug Profile | 117 | 2 |
| DV-2DeltaGVII Drug Profile | 119 | 1 |
| DV-2DeltaLIG Drug Profile | 120 | 1 |
| DV-2G460P Drug Profile | 121 | 2 |
| FDX-000 Drug Profile | 123 | 1 |
| fenretinide Drug Profile | 124 | 1 |
| FX-06 Drug Profile | 125 | 2 |
| GBV-001 Drug Profile | 127 | 1 |
| GBV-006 Drug Profile | 128 | 1 |
| GREDEN/V1-4 Drug Profile | 129 | 1 |
| KIN-1148 Drug Profile | 130 | 1 |
| KIN-1400 Drug Profile | 131 | 1 |
| LCTA-949 Drug Profile | 132 | 1 |
| LVM-142 Drug Profile | 133 | 1 |
| modipafant Drug Profile | 134 | 1 |
| Monoclonal Antibodies for Dengue Drug Profile | 135 | 1 |
| Monoclonal Antibodies to Target Virion, prM and E Proteins for Dengue Drug Profile | 136 | 1 |
| Monoclonal Antibody for Dengue Drug Profile | 137 | 1 |
| Monoclonal Antibody for Dengue Drug Profile | 138 | 1 |
| Peptides for Infectious Diseases Drug Profile | 139 | 1 |
| PY-2 Drug Profile | 140 | 1 |
| QR-211 Drug Profile | 141 | 1 |
| Recombinant Peptide to Inhibit Dengue Protease for Dengue Drug Profile | 142 | 1 |
| RKP-00156 Drug Profile | 143 | 1 |
| RS-1137 Drug Profile | 144 | 1 |
| RS-1142 Drug Profile | 145 | 1 |
| RS-1145 Drug Profile | 146 | 1 |
| RS-930 Drug Profile | 147 | 1 |
| RS-961 Drug Profile | 148 | 1 |
| Small Molecule for Dengue Drug Profile | 149 | 1 |
| Small Molecule for Dengue Drug Profile | 150 | 1 |
| Small Molecule for Dengue Drug Profile | 151 | 1 |
| Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection Drug Profile | 152 | 1 |
| Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections Drug Profile | 153 | 1 |
| Small Molecule to Inhibit RNA Dependent RNA Polymerase for Dengue Drug Profile | 154 | 1 |
| Small Molecule to Target Envelope Protein for Dengue Drug Profile | 155 | 1 |
| Small Molecules for Dengue Drug Profile | 156 | 1 |
| Small Molecules to Activate AMPK for Dengue Drug Profile | 157 | 1 |
| Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections Drug Profile | 158 | 2 |
| Small Molecules to Inhibit Furin for Dengue Drug Profile | 160 | 1 |
| Small Molecules to Inhibit M Protein for Dengue Drug Profile | 161 | 1 |
| Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections Drug Profile | 162 | 1 |
| Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections Drug Profile | 163 | 1 |
| Small Molecules to Inhibit Pan Polymerase for Dengue Drug Profile | 164 | 1 |
| Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections Drug Profile | 165 | 1 |
| Small Molecules to Inhibit Serine Protease for Viral Infections Drug Profile | 166 | 1 |
| Small Molecules to Target Envelope Protein for Dengue Drug Profile | 167 | 1 |
| ST-148 Drug Profile | 168 | 2 |
| ST-324 Drug Profile | 170 | 2 |
| ST-610 Drug Profile | 172 | 1 |
| Synthetic Peptide for Dengue Drug Profile | 173 | 1 |
| Synthetic Peptide for Dengue Virus and West Nile Virus Infections Drug Profile | 174 | 1 |
| TAK-003 Drug Profile | 175 | 3 |
| TDEN-PIV Drug Profile | 178 | 1 |
| TV-003 Drug Profile | 179 | 2 |
| TVX-005 Drug Profile | 181 | 1 |
| UV-4B Drug Profile | 182 | 1 |
| V-180 Drug Profile | 183 | 1 |
| Viral PMO-X Drug Profile | 184 | 1 |
| VIS-513 Drug Profile | 185 | 2 |
| Dengue Fever Dormant Projects | 187 | 5 |
| Dengue Fever Discontinued Products | 192 | 1 |
| Dengue Fever Product Development Milestones | 193 | 14 |
| Featured News &Press Releases | 193 | 1 |
| Apr 15, 2016: Strategic Advisory Group Of Experts On Immunization Convened By The World Health Organization Recommends Use Of Sanofi Pasteur's Dengue Vaccine In Endemic Countries | 193 | 1 |
| Apr 04, 2016: Worlds First Public Dengue Immunization Program Starts in the Philippines | 193 | 1 |
| Mar 16, 2016: Last piece of dengue vaccine puzzle found effective in small trial | 194 | 2 |
| Jan 14, 2016: Dengue vaccine enters phase 3 trial in Brazil | 196 | 1 |
| Dec 28, 2015: Dengvaxia First Dengue Vaccine Approved in Brazil | 196 | 1 |
| Dec 22, 2015: Sanofi Pasteur Dengue Vaccine Approved In The Philippines | 197 | 1 |
| Dec 22, 2015: Sanofi Pasteur's Dengue Vaccine Approved In The Philippines | 198 | 1 |
| Dec 09, 2015: Dengvaxia, World's First Dengue Vaccine, Approved in Mexico | 199 | 1 |
| Sep 22, 2015: Serum Institute of India Plans To Seek Fast-track Approval For Dengue Treatment | 200 | 1 |
| Jul 29, 2015: Inovio Pharmaceuticals' DNA-Based Monoclonal Antibody Protects Animals Against Lethal Challenge | 201 | 1 |
| Jul 27, 2015: New England Journal Of Medicine Publishes New Analyses Confirming That Sanofi Pasteur's Vaccine Candidate Safely Protects Pre-Adolescents To Adults Against Dengue | 201 | 2 |
| Jul 16, 2015: Visterra Announces Publication in the Journal Cell, Demonstrating That Novel Antibody, VIS513, Broadly Neutralizes All Four Serotypes of Dengue Virus in Preclinical Studies | 203 | 1 |
| Nov 03, 2014: The New England Journal of Medicine publishes Results of Final Landmark Phase III efficacy clinical study of Sanofi Pasteur s Dengue Vaccine candidate | 203 | 1 |
| Sep 03, 2014: Sanofi Pasteur s Dengue Vaccine Candidate Successfully Completes Final Landmark Phase III Clinical Efficacy Study in Latin America | 204 | 2 |
| Sep 03, 2014: Visterra to Present Data at ICAAC on VIS513, Its Humanized Monoclonal Antibody That Targets a Conserved Site on the Dengue Virus E Protein | 206 | 1 |
| Appendix | 207 | 2 |
| Methodology | 207 | 1 |
| Coverage | 207 | 1 |
| Secondary Research | 207 | 1 |
| Primary Research | 207 | 1 |
| Expert Panel Validation | 207 | 1 |
| Contact Us | 207 | 1 |
| Disclaimer | 208 | 1 |